<DOC>
	<DOC>NCT01596816</DOC>
	<brief_summary>The aim of this study is to assess the safety of hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).</brief_summary>
	<brief_title>Hypofractionated Stereotactic Boost in Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Prostate adenocarcinoma proved by histology With at least one of this intermediaterisk criterias: T2b and/or PSA between 10 et 20 ng/ml and/or Gleason score = 7 Prostatic volume â‰¤ 80 cc No adenopathy(lymph node &lt; 1.5 cm on scanner or MRI and/or in lymph node dissection) No metastasis (bone scan) Age &gt;= 18 ans No prior pelvic irradiation No prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy &gt; 3 months) Performance status (ECOG) &lt; 1 No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation Life expectancy &gt;= 10 weeks Patient affiliated to health insurance Informed consent signed by the patient Cancer no histologically proved Unfavorablerisk(T2c and/or PSA &gt; 20 ng/ml and/or Gleason &gt; 7) Favorablerisk(T1c T2a and PSA &lt; 10 ng/ml and Gleason &lt; 7) T3 and T4 History of cancer uncontrolled and/or treated since less of 5 years (except basal cell carcinoma of the skin) Contraindication to MRI IPSS score &gt; 10 Recurrent or metastatic disease Allergy to gold Patient already included in another therapeutic trial with an experimental molecule Unable for medical followup (geographic, social or mental reasons)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>